Epilepsy Bio

The EpilepCell™ (aka JadiCell™) is unique in that it possesses features of mesenchymal stem cells, however, EpilepCells outperform these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic
and neurogenic ability.

EpilepCells

Mesenchymal Stem Cell Therapy of Epilepsy and Seizure Disorders
Application No.: 63/41886

Disclosed are novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes. In one embodiment umbilical cord mesenchymal stem cells are administered to a patient suffering from epilepsy at a concentration and frequency sufficient to inhibit neuronal hyperactivation and/or reduce neuroinflammatory status of the patient

Temporal lobe epilepsy (TLE) is a chronic disease characterized by spontaneous, progressive seizures. In many patients, TLE is initiated by brain injury, strokes, tumors or status epilepticus (SE), which is often followed by a latency period of 5–10 years before the onset of spontaneous recurrent motor seizure (SRMS). SE is defined as a continuous seizure activity lasting more than 5 min. SRMS is the repeated unprovoked seizures that occurs in the chronic phase of epilepsy. The main physiopathological findings observed in TLE are neuronal loss, reactive gliosis, aberrant mossy fiber sprouting and spontaneous recurrent motor seizure (SRMS). Antiepileptic drugs fail to well-control seizures in approximately 30% of epilepsy patients.

There is a significant need in the field to develop means of controlling seizures and/or reversing epilepsy.